Pharma Industry News

New data reinforce effectiveness of Novartis’ Zolgensma for SMA

The Phase III STR1VE data showed that 21 patients were alive and event-free as of September 27 last year.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]